Gout is the most prevalent inflammatory arthritis in North America, affecting approximately 3.8% of the population in Canada and 5.1% in the United States (US). Epidemiological modeling through 2050 projects that high-income North America will sustain the highest age-standardized prevalence of gout globally. This rising burden is accompanied by heavy socioeconomic costs and striking demographic shifts. Driven by obesity, early-onset gout among American youth escalated by 63% over the last three decades, while nearly one-third of US adolescents now exhibit hyperuricemia, in contrast to ~20% of adults. Furthermore, profound racial inequities persist; Black patients experience a five-fold higher rate of emergency department (ED) visits for gout flares compared to White patients, and older Asian Americans face the highest overall prevalence. Primary care providers manage 70% to 80% of gout cases in both nations. Suboptimal longitudinal care has led to severe reliance on acute services. Post-ED care continuity remains poor, frequently resulting in low rates of follow-up serum urate testing, high readmission rates, and inappropriate opioid prescribing. Diagnostically, polarizing light microscopy of synovial fluid remains the gold standard, supplemented by advanced ultrasound and dual-energy computed tomography imaging, although this technology is limited by provider availability. Treatment paradigms prioritize a treat-to-target strategy to maintain serum urate levels below 6 mg/dL. Allopurinol is the preferred first-line therapy, with recent clinical data validating its safety and efficacy when progressively titrated in patients with chronic kidney disease. Second-line febuxostat requires shared decision making in the context of cardiovascular disease, while advanced, refractory tophaceous gout is managed in the US with intravenous pegloticase which can be co-administered with methotrexate to mitigate immunogenicity. Ultimately, optimizing North American gout outcomes requires improvement in health services delivery with multidisciplinary models of care serving as an emerging solution.
No takes yet. Share an insight, caveat, or question.
Sudireddy et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: